Clinical Trial: Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma

U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07514793) titled 'Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma' on March 31.

Brief Summary: This is a prospective, single-arm, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of iparomlimab and tuvoraleimab in combination with bevacizumab and chemotherapy as first-line treatment for advanced mesothelioma.

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: Mesothelioma

Intervention: DRUG: Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin

Iparomlimab and Tuvoraleimab: 5 mg/kg each, on Day 1, intrav...